Combined Therapy Improved Salivary Flow in Cancer Patients
A study explored whether combining two therapies helps restore saliva production in head and neck cancer patients.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Should patients trust medical study findings that are based on very small participant groups?
Researchers evaluated a combination of photobiomodulation and pilocarpine hydrochloride to treat hyposalivation in 24 head and neck cancer patients. The approach was examined for its potential to improve salivary flow following radiochemotherapy.
Why it matters
Hyposalivation is a frequent complication for patients undergoing radiochemotherapy, which can significantly impact quality of life. This research aimed to identify more effective ways to manage this side effect through combined treatment regimens.
In a randomized trial of 24 head and neck cancer patients, researchers measured salivary flow and pH across three treatment groups. While the primary endpoint showed no significant difference, the combined group saw an increased flow between the end of treatment and a 3-month follow-up.
The details
The study randomized patients into pilocarpine, photobiomodulation, or combined treatment groups to address radiation-induced salivary gland damage. By comparing these modalities, researchers assessed if integrating pharmacological stimulation with light therapy could produce a synergistic effect. The team tracked salivary flow rates, pH, and electrolyte concentrations from baseline through a 3-month follow-up period.
Timeline
August 21, 2023: The clinical trial was registered in the ISRCTN registry.
Baseline: Initial salivary assessments were performed.
End of RCT: Secondary salivary assessments were performed.
3-month follow-up: Final salivary assessments were performed.
Health Landscape
This study is part of ongoing efforts in the ISRCTN registry to address common radiation-induced toxicities that lack standardized solutions. It adds to a growing body of research evaluating how non-invasive light therapies might enhance the efficacy of traditional pharmaceutical treatments.
If you are experiencing dry mouth during or after radiochemotherapy, it is worth discussing potential supportive care options with your oncology team. Because this study only included 24 people, current findings remain preliminary and should be viewed as a subject to monitor with your doctor.
The takeaway
While this combination shows early potential for addressing radiation-induced hyposalivation, current evidence is limited to small-scale trials. Patients should keep a log of their symptoms and share any changes in mouth comfort with their care team during follow-up appointments.
Further reading
For more information on managing side effects during treatment, visit our Cancer section.
More information
Review the full ISRCTN clinical trial registration for additional study design details.
Source note: This article includes information reported by Nature.
Live Poll
Should patients trust medical study findings that are based on very small participant groups?
